Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light

• US 7,985,588 B2
• Filed: 10/31/2007
• Issued: 07/26/2011
• Est. Priority Date: 06/02/2000
• Status: Expired due to Fees

• Current Assignee: Terumo BCT Biotechnologies, LLC (Terumo Corporation)
• Original Assignee: Caridianbct Biotechnologies LLC (Baxter International Inc.)
• Inventors: Keil, Shawn D., Goodrich, Raymond P.
• Primary Examiner(s): Noakes; Suzanne
• Assistant Examiner(s): Lee; Jae W
• Application Number:
  US11/932,629
• Publication Number:
  US 20080107636A1
• Time in Patent Office: 1,364 Days
• Field of Search: None
• US Class Current: 435/375
• CPC Class Codes: A01N 2300/00 Combinations or mixtures of active ingredients covered by classes A01N27/00 - A01N65/48 with other active or formulation relevant ingredients, e.g. specific carrier materials or surfactants, covered by classes A01N25/00 - A01N65/48
• CPC Class Codes: A01N 25/00 Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application , e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
• CPC Class Codes: A01N 43/90 having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• CPC Class Codes: A61K 41/17 by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
• CPC Class Codes: A61L 2/0011 using physical methods
• CPC Class Codes: A61L 2/0082 using chemical substances
• CPC Class Codes: A61L 2/0088 Liquid substances
• CPC Class Codes: A61L 2/08 Radiation
• CPC Class Codes: A61L 2/084 Visible light
• CPC Class Codes: A61L 2/10 Ultraviolet radiation
• CPC Class Codes: A61L 2202/22 Blood or products thereof
• CPC Class Codes: A61M 1/0213 with isolated sections of the tube used as additive reservoirs
• CPC Class Codes: A61M 1/3681 by irradiation
• CPC Class Codes: A61M 1/3683 using photoactive agents
• CPC Class Codes: A61M 1/3693 using separation based on different densities of components, e.g. centrifuging
• CPC Class Codes: A61M 2205/123 with incorporated reservoirs

Abstract

A process for damaging and maintaining damage to the nucleic acids of pathogens such as white blood cells, bacteria and viruses which may be contained in blood or blood components. This process comprises adding to the blood or blood component containing pathogens an effective amount of riboflavin, and exposing the fluid to light of an appropriate wavelength to damage the nucleic acid of the pathogen and to substantially maintain the damage to the pathogenic nucleic acids to allow for subsequent transfusion into a recipient.

Claims

1. A process for inactivating or inhibiting the proliferation of mononuclear cells in response to a stimulus comprising the steps of:

adding to the mononuclear cells 500 μ

M riboflavin and irradiating said mononuclear cells with 6.2 J UV light/mL for approximately 8-10 minutes to make treated mononuclear cells;

exposing the treated mononuclear cells to a stimulus; and

thereby

inactivating or inhibiting the proliferation of the treated mononuclear cells in response to the stimulus.

2. The process of claim 1 wherein the exposing step further includes the step of exposing the treated mononuclear cells to mitogens, allogeneic stimulator cells and antibodies.

3. The process of claim 1 whereby the treated mononuclear cells are human.

4. A process for inhibiting the antigen presentation capabilities of mononuclear cells comprising the step of:

adding to the mononuclear cells 500 μ

M riboflavin and irradiating with 6.2 J UV light/mL for approximately 8-10 minutes to make treated mononuclear cells;

wherein the antigen presentation capabilities of the treated mononuclear cells are inhibited.

5. A process for inactivating or inhibiting cytokine production by mononuclear cells in response to a stimulus comprising the steps of:

adding to the mononuclear cells 500 μ

M riboflavin and irradiating said mononuclear cells with 6.2 J UV light/mL for approximately 8-10 minutes to make treated mononuclear cells;

exposing the treated mononuclear cells to a stimulus; and

thereby

inactivating or inhibiting the production of cytokines in response to the stimulus.

6. The process of claim 5 wherein the exposing step further includes the step of exposing the treated mononuclear cells to mitogens, allogeneic stimulator cells and antibodies.

7. The process of claim 5 whereby the treated mononuclear cells are human.